Citius Oncology, Inc. (CTOR) stock
CTORNasdaqPharmaceutical PreparationsFiscal year ends September 30
$0.55+0.01 (+2.36%)
Close on Nov 17, 2026Market cap $50.92MP/E –Yield –
Citius Oncology operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Citius Oncology's operating income for the twelve months ending Jun 30, 2026 was -$47.29M. For fiscal 2025 it was -$23.52M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -$23.52M | – |
| FY2022 | Dec 31, 2022 | -$138.12K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -$8.72M | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$28.61M | – |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -$5.25M | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -$4.71M | – |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -$4.94M | – |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | -$7.47M | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$6.39M | – |
See a number that looks wrong?